Cargando…

LncRNA H19 Impairs Chemo and Radiotherapy in Tumorigenesis

Various treatments based on drug administration and radiotherapy have been devoted to preventing, palliating, and defeating cancer, showing high efficiency against the progression of this disease. Recently, in this process, malignant cells have been found which are capable of triggering specific mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Padilla, Carlos, Lozano-Velasco, Estefanía, Muñoz-Gallardo, María del Mar, Castillo-Casas, Juan Manuel, Caño-Carrillo, Sheila, Martínez-Amaro, Francisco José, García-López, Virginio, Aránega, Amelia, Franco, Diego, García-Martínez, Virginio, López-Sánchez, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368906/
https://www.ncbi.nlm.nih.gov/pubmed/35955440
http://dx.doi.org/10.3390/ijms23158309
Descripción
Sumario:Various treatments based on drug administration and radiotherapy have been devoted to preventing, palliating, and defeating cancer, showing high efficiency against the progression of this disease. Recently, in this process, malignant cells have been found which are capable of triggering specific molecular mechanisms against current treatments, with negative consequences in the prognosis of the disease. It is therefore fundamental to understand the underlying mechanisms, including the genes—and their signaling pathway regulators—involved in the process, in order to fight tumor cells. Long non-coding RNAs, H19 in particular, have been revealed as powerful protective factors in various types of cancer. However, they have also evidenced their oncogenic role in multiple carcinomas, enhancing tumor cell proliferation, migration, and invasion. In this review, we analyze the role of lncRNA H19 impairing chemo and radiotherapy in tumorigenesis, including breast cancer, lung adenocarcinoma, glioma, and colorectal carcinoma.